Available Technologies
# of Displayed Technologies: 5 / 5
Applied Category Filter (Click To Remove): Vaccines
A next generation intranasal trivalent Measles, Mumps and Covid vaccine
TS-064189 — The Need
The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Xu, Jiayu; Zhang, Yuexiu
- Licensing Officer: Willson, Christopher
Live Attenuated Mumps Virus-Based SARS-CoV-2 Vaccines for Infants and Children
TS-062231 — The Need: Addressing the Urgent Need for a Safe and Effective SARS-CoV-2 Vaccine for Infants and Children
The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has brought about significant economic, emotional, and public health challenges worldwide. The pressing dema…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; Boyaka, Prosper; Lu, Mijia; Zhang, Yuexiu
- Licensing Officer: Willson, Christopher
Novel method for attenuating live vaccine candidates for non-segmented negative-sense RNA viruses
TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease
Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…
- College: College of Veterinary Medicine
- Inventors: Li, Jianrong; He, Chuan; Lu, Mijia; Niewiesk, Stefan; Peeples, Mark; Xue, Miaoge; Zhang, Zijie; Zhao, Boxuan
- Licensing Officer: Willson, Christopher
Novel Live Attenuated Vaccines for Human Metapneumovirus
TS-037675 — Novel method of using live attenuated vaccines to prevent infection of hMVP.
The Need: Human metapneumovirus (hMPV) is a prevalent pathogen causing acute respiratory tract disease in individuals of all ages, especially infants, children, the elderly, and immunocompromised individuals. Despite its global prevalence, there are currently no therapeutics or vaccines available fo…
- College: College of Food, Agricultural, and Environmental Sciences (CFAES)
- Inventors: Li, Jianrong; Wei, Yongwei; Zhang, Yu
- Licensing Officer: Dahlman, Jason "Jay"
Novel Vaccine for Respiratory Syncytial Virus
TS-037299 — Recombinant vesicular stomatitis virus (rVSV) vaccines to fight against respiratory syncytial virus (RSV) infections.
The Need: Respiratory Syncytial Virus (RSV) is a major cause of infant hospitalization due to acute lower respiratory tract infections (ALRI) in children under 5 years of age globally, causing up to 200,000 deaths annually. RSV leads to significantly more hospitalizations than influenza in children …
- College: College of Veterinary Medicine
- Inventors: Niewiesk, Stefan; Binjawadagi, Basavaraj; Li, Jianrong; Peeples, Mark
- Licensing Officer: Willson, Christopher
